Seattle Genetics is one of the many companies that is making headway in cancer research in the recent past. Clay Siegall has been at the helm of the company, diligently helping in improving cancer patient’s lives. Since 2002, he has been the executive officer, and with great skills, he has led the company in making great strides in cancer research and innovative therapies.
Leadership and Growth
Throughout his career, Clay Siegall has been passionate about helping ease the pain for cancer patients. It’s with this drive that he has provided the much-needed leadership that has elevated Seattle Genetics to a position of executing high-end research developments. The company has since developed their first antibody drug conjugates, such as ADCETRIS. Clay Siegall played a big part in ensuring that ADCETRIS gained FDA approval in 2011. He, as well, helped popularize ADCETRIS around the world to ensure it reaches as many patients as possible.
Achievements and Awards
Besides his leadership role in new cancer therapies sector, Siegall has also helped in raising more than 1.2 billion dollars as capital for Seattle Genetics in private and public funding. Since its inception in 1998, Seattle Genetics has grown rapidly, with their stock having tripled in only less than half a decade under the able management of Clay Siegall. His efforts haven’t gone unrecognized as he was named the Entrepreneur of the Year in 2012. In 2013, he was granted the Maryland Alumnus of the Year for Natural Sciences, Math, and Computer.
Clay Siegall spent three years at George Washington University and completed his Ph.D. in Genetics. He began working at the Bristol-Myers as a chief investigator. He rose through the ranks to the principal scientist post. He advanced to become a member of staff at the National Cancer Institute. Shortly after, Siegall participated in setting up Seattle Genetics.
Clay Siegall owns 15 patents and is still dedicated to looking for ways to improve cancer research. Clay Siegall has been generous to share his in-depth background in the medical field with the community. His passion for educating the scientific community has seen him publish more than 70 articles in medical and science matters.